Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Equities research analysts at HC Wainwright dropped their FY2024 earnings estimates for Dianthus Therapeutics in a research report issued on Monday, November 11th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($3.06) for the year, down from their previous estimate of ($2.33). HC Wainwright has a "Buy" rating and a $40.00 price target on the stock. The consensus estimate for Dianthus Therapeutics' current full-year earnings is ($2.52) per share. HC Wainwright also issued estimates for Dianthus Therapeutics' Q4 2024 earnings at ($1.14) EPS, Q1 2025 earnings at ($1.21) EPS, Q2 2025 earnings at ($1.29) EPS, Q3 2025 earnings at ($1.06) EPS, Q4 2025 earnings at ($0.91) EPS, FY2025 earnings at ($4.47) EPS, FY2026 earnings at ($4.89) EPS, FY2027 earnings at ($4.61) EPS and FY2028 earnings at ($3.94) EPS.
Other equities research analysts have also issued research reports about the company. Baird R W raised Dianthus Therapeutics to a "strong-buy" rating in a research report on Friday, July 26th. Raymond James lifted their price target on shares of Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an "outperform" rating in a research note on Friday, November 8th. Wedbush dropped their price objective on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an "outperform" rating on the stock in a research report on Friday, August 9th. Oppenheimer lifted their price objective on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an "outperform" rating in a research report on Monday. Finally, Robert W. Baird assumed coverage on shares of Dianthus Therapeutics in a research note on Friday, July 26th. They set an "outperform" rating and a $58.00 target price for the company. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Dianthus Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $46.43.
Check Out Our Latest Stock Analysis on DNTH
Dianthus Therapeutics Price Performance
Shares of DNTH stock traded up $0.88 on Thursday, hitting $27.23. The stock had a trading volume of 1,708,133 shares, compared to its average volume of 202,856. The firm has a market capitalization of $805.93 million, a P/E ratio of -10.54 and a beta of 1.84. Dianthus Therapeutics has a 1 year low of $6.58 and a 1 year high of $33.77. The company's 50 day moving average price is $27.70 and its 200-day moving average price is $26.64.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.15). The company had revenue of $2.17 million during the quarter, compared to analysts' expectations of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%.
Institutional Trading of Dianthus Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in DNTH. Quest Partners LLC increased its position in Dianthus Therapeutics by 112,400.0% during the third quarter. Quest Partners LLC now owns 1,125 shares of the company's stock worth $31,000 after buying an additional 1,124 shares during the period. SG Americas Securities LLC acquired a new stake in shares of Dianthus Therapeutics during the second quarter worth about $112,000. The Manufacturers Life Insurance Company purchased a new position in shares of Dianthus Therapeutics during the second quarter worth about $236,000. WINTON GROUP Ltd acquired a new position in Dianthus Therapeutics in the 2nd quarter valued at about $265,000. Finally, Point72 DIFC Ltd purchased a new stake in Dianthus Therapeutics during the 2nd quarter valued at approximately $334,000. 47.53% of the stock is owned by hedge funds and other institutional investors.
About Dianthus Therapeutics
(
Get Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Featured Stories
Before you consider Dianthus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dianthus Therapeutics wasn't on the list.
While Dianthus Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
